IN THE CLAIMS:

Please cancel claims 6 and 24, and amend claims 1, 2, 4, 5, 7, and 23. Please add claims 25-31. This listing of claims will replace all prior versions, and listings, of claims in the application:

STATUS OF THE CLAIMS:

1. (Currently Amended): A method for identifying a ~~candidate~~ compound capable of treating urinary incontinence~~a urological disorder~~, comprising:

a) combining a compound to be tested with a sample comprising a polypeptide selected from the group consisting of:

i) a polypeptide comprising the amino acid sequence of SEQ ID NO:104; and

ii) a polypeptide encoded by the nucleotide sequence set forth in SEQ ID NO:103;

under conditions suitable for binding of the ~~test~~ compound to the polypeptide; and

b) detecting binding of the ~~test~~ compound to the polypeptide to thereby identify a compound which binds to the polypeptide;

thereby identifying a compound capable of treating urinary incontinence~~a urological disorder~~.

2. (Currently Amended): The method of claim 1, wherein the compound is selected from the group consisting of a small molecule, a peptide and~~or~~ an antibody.

3. (Previously Presented): The method of claim 1, wherein the polypeptide further comprises heterologous sequences.

4. (Currently Amended): The method of claim 1, wherein the sample comprises the~~an isolated~~ polypeptide, a membrane-bound form of the~~an isolated~~ polypeptide or a cell comprising the polypeptide.

5. (Currently Amended): The method of claim 4, wherein the cell is selected from the group consisting of a bladder cell, a prostate cell, a kidney cell, a vascular cell, a urethral cell, a dorsal root ganglion cell, a trigeminal ganglion cell, a brain cell, and a spinal cord cell~~a urological cell~~.

6. (Canceled)

7. (Currently Amended): The method of claim 1, wherein ~~the~~ binding of the ~~test~~ compound to the polypeptide is detected by a method selected from the group consisting of:

a) a competition binding assay;

b) an immunoassay; and

c) a yeast two-hybrid assay.

8-22. (Canceled)

23. (Currently Amended): The method of claim 1, wherein binding of the ~~test~~ compound to the polypeptide is detected by an assay for an activity of the polypeptide selected from the group consisting of:

a) a carboxypeptidase assay; and

b) an assay for measuring proteolysis of extracellular peptides or proteins.

24. (Canceled):

25. (New): A method for identifying a compound capable of treating benign prostatic hyperplasia, comprising:

a) combining a compound to be tested with a sample comprising a polypeptide selected from the group consisting of:

i) a polypeptide comprising the amino acid sequence of SEQ ID NO:104; and

ii) a polypeptide encoded by the nucleotide sequence set forth in SEQ ID NO:103;

under conditions suitable for binding of the compound to the polypeptide; and

b) detecting binding of the compound to the polypeptide to thereby identify a compound which binds to the polypeptide;

thereby identifying a compound capable of treating benign prostatic hyperplasia.

26. (New): The method of claim 25, wherein the compound is selected from the group consisting of a small molecule, a peptide and an antibody.

27. (New): The method of claim 25, wherein the polypeptide further comprises heterologous sequences.

28. (New): The method of claim 25, wherein the sample comprises the polypeptide, a membrane-bound form of the polypeptide or a cell comprising the polypeptide.

29. (New): The method of claim 28, wherein the cell is selected from the group consisting of a bladder cell, a prostate cell, a kidney cell, a vascular cell, a urethral cell, a dorsal root ganglion cell, a trigeminal ganglion cell, a brain cell, and a spinal cord cell.

30. (New): The method of claim 25, wherein binding of the compound to the polypeptide is detected by a method selected from the group consisting of:

a) a competition binding assay;

b) an immunoassay; and

c) a yeast two-hybrid assay.

31. (New): The method of claim 25, wherein binding of the compound to the polypeptide is detected by an assay for an activity of the polypeptide selected from the group consisting of:

a) a carboxypeptidase assay; and

b) an assay for measuring proteolysis of extracellular peptides or proteins.